Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase trials in relapsed patients to a viable therapeutic approach with predictable efficacy and low toxicity for broad application among patients with high unmet need is currently complicated by product heterogeneity res...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood
Main Authors: Gardner, Rebecca A., Finney, Olivia, Annesley, Colleen, Brakke, Hannah, Summers, Corinne, Leger, Kasey, Bleakley, Marie, Brown, Christopher, Mgebroff, Stephanie, Kelly-Spratt, Karen S., Hoglund, Virginia, Lindgren, Catherine, Oron, Assaf P., Li, Daniel, Riddell, Stanley R., Park, Julie R., Jensen, Michael C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2017
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482103/
https://ncbi.nlm.nih.gov/pubmed/28408462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-02-769208
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki